Jun 12, 2020
Integral Molecular Provides Rapid Safety Testing of COVID-19 Antibody Therapeutics with its Membrane Proteome Array Technology
Apr 30, 2020
Integral Molecular Develops Test for Neutralizing Antibodies in COVID-19 Patients and Clinical Trials
Apr 23, 2020
Integral Molecular Receives NIAID Award to Combat COVID-19
Mar 09, 2020
Integral Molecular Accelerates Coronavirus Vaccine Research
Feb 13, 2020
Integral Molecular Launches ReadyMap Services for Rapid, Conformational Epitope Mapping
Jan 09, 2020
Integral Molecular Announces Preclinical P2X7 Antibody Assets for Autoimmune Disorders
Nov 14, 2019
Integral Molecular to Advance Vaccine Discovery with NIH Contract for $5.5M
Sep 26, 2019
Integral Molecular Selected as the First Industry Partner in The Wistar Institute's Biomedical Research Technician Apprenticeship
Jun 26, 2019
Integral Molecular Presents Data on Monoclonal Antibodies (MAbs) Against SLC2A4 (GLUT4), a Critical Target for Diabetes
May 28, 2019
Integral Molecular Reaches Milestone in Immuno-Oncology Target Discovery Collaboration with Daiichi Sankyo
Mar 26, 2019
Integral Molecular to Present Claudin 6 MAbs, a Therapeutic Asset for Solid Tumors, at Annual AACR Conference
Jan 07, 2019
Integral Molecular Enters Immuno-Oncology Target Discovery Collaboration with Daiichi Sankyo
Jan 03, 2019
Integral Molecular Announces Antibody Discovery Collaboration with Ono Pharmaceutical
Dec 04, 2018
Integral Molecular's Therapeutic MAbs Against CB1 to Treat NASH Enter New Development Phase Following $1.4M NIH Award